Previous 10 | Next 10 |
2023-07-26 15:04:29 ET The World Health Organization updated its Essential Medicines List on Wednesday without adding a class of weight loss medications called glucagon-like peptide-1 (GLP-1) receptor agonists as a treatment for obesity. The list designed to guide state procurement deci...
2023-07-25 08:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-24 02:54:50 ET Summary Kodiak Sciences shows improved financial performance in Q1 2023, and it's actively developing treatments for prevalent retinal diseases. Kodiak's primary candidate, tarcocimab, is undergoing several clinical trials, aiming to provide a potent anti-VE...
2023-07-16 12:00:00 ET While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later this month, Barclays has picked Eli Lilly ( NYSE: LLY ) and Merck ( NYSE: MRK ) as two of the most favorably positioned ...
2023-07-15 18:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-15 01:13:39 ET Summary Regeneron Pharmaceuticals faced a setback as the FDA rejected the approval of an 8mg dose of its eye disease therapy, Eylea, leading to an 8% drop in shares. Despite the setback, Regeneron reported a 7% increase in total revenues in Q1 2023, driven b...
2023-07-07 10:15:03 ET Summary Shares of "directed evolution" genetic medicine concern 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. The company’s approach to AAV delivery could change the industry, but resul...
2023-07-07 07:00:00 ET Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently took a significant blow, dropping by 8% in one day. For a comp...
2023-07-07 05:07:59 ET Summary Regeneron's stock price has suffered a setback due to concerns over the future of Eylea, its flagship drug, as competition and potential drug pricing regulations loom. The company's immunology collaboration with Sanofi continues to show promise, part...
2023-07-06 07:50:00 ET Regeneron Pharmaceuticals ' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for driving sales higher in the future. However, last week the Food ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...